Human Erythropoietin (hEPO) #6980
Inquiry Info. # 6980
Please see our recommended alternatives.
Product Information
Product Usage Information
Reconstitution:
With carrier: Add sterile PBS or PBS containing 1% bovine or human serum albumin or 5-10% FBS to a final hEPO concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.
Carrier free: Add sterile PBS or PBS containing protein to minimize absorption of hEPO to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock hEPO should be greater than 50 μg/ml.
Formulation
Storage
Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
Product Description
| MW (kDa) | 34-40 |
| Purity | >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hEPO. All lots are greater than 98% pure. |
| Endotoxin | Less than 0.01 ng endotoxin/1μg hEPO. |
| Activity | The bioactivity of recombinant hEPO was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 50-400 pg/ml. |
| Molecular Formula | Recombinant hEPO contains no "tags" and the nonglycosylated protein has a calculated MW of 20,417. DTT-reduced and non-reduced protein migrate as 34-40 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation. The expected amino-terminal APPRL of recombinant hEPO was verified by amino acid sequencing. |
Source / Purification
Recombinant human Erythropoietin (hEPO) Ala28-Arg193 (Accession #NP_000790) was expressed in human 293 cells at Cell Signaling Technology.
Background
EPO is a 34 kDa protein that is required for the survival and terminal differentiation of erythrocytes (1). EPO is produced by a number of cell types including tubular endothelial cells, interstitial cells, hepatocytes, Kupffer cells, astrocytes, and Schwann cells (2-4). EPO inhibits apoptosis and may protect neuronal cells from death during ischemia and/or neurodegenerative diseases (3,4). EPO inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling (5). EPO protected against the development of diabetes in an animal model by promoting pancreatic β cell survival and growth (6). Binding of EPO to its cognate receptor, EPOR, induces activation of Jak2, Stat5 and Akt (3-5).
Product Citations: 1
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.